ARCHIVES

Adjuvant XELOX More Effective Than 5-FU/LV For Stage III Colon Cancer

This article is from The Cancer Letter archive.

Vol. 33 No. 1 | January 29, 2010

Download PDF Visit The Full Archive

Related Articles

Preventive Ovarian Surgery Recommended For Women with BRCA1 Mutations by Age 35

February 28, 2014

FDA Approves Gleevec In 73 Days, A Speed Record.

May 18, 2001

Cancer Groups Propose Six Characteristics Of Next FDA Head.

December 19, 2008

In Brief: NCAB Still Without New Appinees As Carter, Califano Delay Drags On; Keele to U. Kansas

January 19, 1979

Scientists Defend NCI, Criticize Post Series As Inaccurate

November 20, 1981

NIH Expands Minority Biomedical Research Training

July 11, 1975